GlassScriptPhysician profile
Amanda J Murray
NPI 1427576453
$1,408.69
in general payments reported to CMS, 2019-2025
25 companies · $21.04 in 2025
The $21.04 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,185 · 2022: $116 · 2024: $86.50 · 2025: $21.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.90 | 2021-2025 | Fasenra |
| Nestle Healthcare Nutrition INC. | $158.82 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $142.69 | 2021 | |
| Organogenesis INC. | $86.50 | 2024 | |
| Glaxosmithkline, LLC. | $68.44 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $63.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.16 | 2021 | |
| Novo Nordisk INC | $46.27 | 2021 | |
| Biogen, INC. | $46.26 | 2021 | |
| Avanir Pharmaceuticals, INC. | $43.99 | 2022 | |
| Lilly USA, LLC | $39.32 | 2021 | |
| Amgen INC. | $39.06 | 2021 | |
| Endo Pharmaceuticals INC. | $38.05 | 2021 | |
| Esperion Therapeutics, INC. | $37.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $36.64 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.95 | 2021 | |
| Acadia Pharmaceuticals INC | $34.22 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $24.79 | 2021 | |
| Neurelis, INC. | $20.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.34 | 2021 | |
| Abbvie INC. | $18.40 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.19 | 2021 | |
| Pfizer INC. | $17.99 | 2021 | |
| Eisai INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.